NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/04/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,186.95 mln
Float74.01 mln
Earnings Date10/29/2026
Piotroski F-Score
4
/ 9
Borderline
1-Year Forecast
33.14
Transformational upside
Relative Strength
45
/ 100
Slightly lagging
Debt / Equity
0.00
Debt-free
ROE
-39.85
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Corvus Pharmaceuticals is a US-based clinical-stage company focused on developing treatments that work by targeting key proteins involved in immune system function. Its pipeline includes three main drug candidates currently in clinical trials for conditions ranging from certain cancers to inflammatory and autoimmune diseases. The company supports its research through licensing partnerships with several academic and commercial organizations. Founded in 2014 and headquartered in South San Francisco, California, Corvus is working to bring forward a new generation of immune-based therapies.
